The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Correspondence
PreviousPrevious
Volume 350:415-416 January 22, 2004 Number 4
NextNext

Schizophrenia, Drug Therapy, and Monitoring

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
-Related Article
by Freedman, R.
-PubMed Citation
To the Editor: In his article on schizophrenia, Freedman (Oct. 30 issue)1 may have understated the relative benefits of clozapine, which has proven advantages over other antipsychotic drugs in mitigating refractory positive and negative symptoms,2 aggression,3 and suicidal behaviors.4 The risk of agranulocytosis and the associated requirement of blood monitoring may reasonably delay the use of clozapine until a trial of at least one other agent has been completed, but clozapine is underused in the treatment of schizophrenia.5 Reasons for this underuse may include both the inconvenience of blood monitoring to reduce the risk of agranulocytosis and physicians' inexperience with . . . [Full Text of this Article]



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.